US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NovaBridge Biosciences

2.54

-0.0100-0.39%

Post-market: 2.540.00000.00%17:30 EDT

Volume:472.50K

Turnover:1.23M

Market Cap:292.78M

PE:-8.42

High:2.74

Open:2.58

Low:2.53

Close:2.55

52wk High:6.79

52wk Low:0.5950

Shares:115.27M

Float Shares:48.23M

Volume Ratio:0.72

T/O Rate:0.98%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3017

EPS(LYR):-0.2738

ROE:-18.46%

ROA:-10.36%

PB:1.13

PE(LYR):-9.28

Loading ...

Overview Company News Filings

NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement

NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement

NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement

NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement

NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong

NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang

NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement

NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Novabridge Biosciences: FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway

THOMSON REUTERS

Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026

THOMSON REUTERS

BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer

NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer

Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

THOMSON REUTERS

Novabridge Biosciences - FDA Confirms Givastomig Eligible for Accelerated Approval Pathway

THOMSON REUTERS

Novabridge Biosciences - to Initiate Registrational Phase 3 Combination Trial in Q4 2026 Using Orr as Primary Endpoint

THOMSON REUTERS

Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease

Benzinga_recent_news

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/NBP/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","market":"US","secType":"STK","nameCN":"NovaBridge Biosciences","latestPrice":2.54,"timestamp":1774641600000,"preClose":2.55,"halted":0,"volume":472500,"hourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.54,"latestTime":"17:30 EDT","volume":888,"amount":2255.62,"timestamp":1774647048954,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.003921568627450897,"floatShares":48234000,"shares":115266053,"eps":-0.30172,"marketStatus":"Market Closed","change":-0.01,"latestTime":"03-27 16:00:00 EDT","open":2.58,"high":2.735,"low":2.53,"amount":1233640.989,"amplitude":0.080392,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.30172,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":2.3,"listingDate":1579237200000,"exchange":"NASDAQ","adjPreClose":2.55,"preHourTrading":{"tag":"盘前","latestPrice":2.67,"preClose":2.55,"latestTime":"09:28 EDT","volume":1217,"amount":3139.3068735,"timestamp":1774618100210,"change":0.12,"changeRate":0.047059,"amplitude":0.058824},"postHourTrading":{"tag":"盘后","latestPrice":2.54,"preClose":2.54,"latestTime":"17:30 EDT","volume":888,"amount":2255.62,"timestamp":1774647048954,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7181013139004255,"impliedVol":0.2776,"impliedVolPercentile":0.0784},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NBP\",,,,,undefined,":{"symbol":"NBP","floatShares":48234000,"roa":"-10.36%","roe":"-18.46%","lyrEps":-0.273814,"volumeRatio":0.7181013139004255,"shares":115266053,"dividePrice":0,"high":2.735,"amplitude":0.080392,"preClose":2.55,"low":2.53,"week52Low":0.595,"pbRate":"1.13","week52High":6.79,"institutionHeld":0,"latestPrice":2.54,"eps":-0.30172,"divideRate":0,"volume":472500,"delay":0,"ttmEps":-0.30172,"open":2.58,"prevYearClose":3.98,"prevWeekClose":2.56,"prevMonthClose":3.28,"prevQuarterClose":3.98,"fiveDayClose":2.56,"twentyDayClose":3.28,"sixtyDayClose":3.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NBP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"NBP","fiscalQuarterEnding":"2025/06","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"pre","actualEps":-0.07},{"market":"US","date":"2025-05-15","symbol":"NBP","fiscalQuarterEnding":"2025/03","expectedEps":-0.07,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.04},{"market":"US","date":"2025-04-03","symbol":"NBP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1743652800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-11-14","symbol":"NBP","fiscalQuarterEnding":"2024/09","expectedEps":-0.16,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2024-08-28","symbol":"NBP","fiscalQuarterEnding":"2024/06","expectedEps":-0.51,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NBP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1759550400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NBP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NBP","date":"2026-03-27","current":-8.418401,"percent":0.94,"low":-20.276437,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"high":-10.607129,"avg":-14.288617,"sd":2.449957,"marketCap":293992129},"quantilePoints":[{"date":"2025-10-31","current":-13.114792,"twenty":-13.114792,"median":-13.114792,"eighty":-13.114792,"marketCap":524460541},{"date":"2025-11-07","current":-12.077138,"twenty":-13.547148,"median":-12.71126,"eighty":-12.278904,"marketCap":482964762},{"date":"2025-11-14","current":-12.019491,"twenty":-13.114792,"median":-12.278904,"eighty":-12.077138,"marketCap":480659441},{"date":"2025-11-21","current":-12.077138,"twenty":-13.085968,"median":-12.293316,"eighty":-12.077138,"marketCap":482964762},{"date":"2025-11-28","current":-11.068308,"twenty":-13.06291,"median":-12.192433,"eighty":-11.881137,"marketCap":442621643},{"date":"2025-12-05","current":-11.500664,"twenty":-12.688201,"median":-12.077138,"eighty":-11.212426,"marketCap":459911551},{"date":"2025-12-12","current":-11.298898,"twenty":-12.411494,"median":-12.033903,"eighty":-11.287368,"marketCap":451842927},{"date":"2025-12-19","current":-17.342266,"twenty":-12.688201,"median":-12.048315,"eighty":-11.460311,"marketCap":456552482},{"date":"2025-12-26","current":-20.276437,"twenty":-13.287734,"median":-12.077138,"eighty":-11.500664,"marketCap":533797473},{"date":"2026-01-02","current":-17.429853,"twenty":-17.342266,"median":-12.163609,"eighty":-11.512194,"marketCap":458858303},{"date":"2026-01-09","current":-16.597774,"twenty":-17.482405,"median":-12.235668,"eighty":-11.541017,"marketCap":436953007},{"date":"2026-01-16","current":-16.028458,"twenty":-17.394818,"median":-12.365376,"eighty":-11.569841,"marketCap":421965173},{"date":"2026-01-23","current":-17.03571,"twenty":-17.342266,"median":-13.057145,"eighty":-11.587135,"marketCap":448482110},{"date":"2026-01-30","current":-16.116045,"twenty":-17.3773,"median":-13.33097,"eighty":-11.615959,"marketCap":424270994},{"date":"2026-02-06","current":-14.583269,"twenty":-17.342266,"median":-14.495682,"eighty":-11.742783,"marketCap":383919133},{"date":"2026-02-13","current":-14.189126,"twenty":-17.307231,"median":-14.71465,"eighty":-11.823489,"marketCap":373542940},{"date":"2026-02-20","current":-14.539475,"twenty":-17.167091,"median":-14.517578,"eighty":-11.961843,"marketCap":382766222},{"date":"2026-02-27","current":-14.364301,"twenty":-17.03571,"median":-14.408094,"eighty":-12.019491,"marketCap":378154581},{"date":"2026-03-06","current":-15.94087,"twenty":-17.03571,"median":-14.386197,"eighty":-12.048315,"marketCap":419659352},{"date":"2026-03-13","current":-12.875318,"twenty":-16.991917,"median":-14.364301,"eighty":-12.077138,"marketCap":338955631},{"date":"2026-03-20","current":-11.780478,"twenty":-16.948123,"median":-14.316021,"eighty":-12.077138,"marketCap":310132873},{"date":"2026-03-27","current":-11.167368,"twenty":-16.597774,"median":-14.189126,"eighty":-11.788901,"marketCap":293992129}],"updateTime":1774751865195},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NBP\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622144080","title":"NovaBridge Biosciences EVP Denny Hsueh Wen Chu Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622144080","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622144080?lang=en_us&edition=fundamental","pubTime":"2026-03-25 08:08","pubTimestamp":1774397339,"startTime":"0","endTime":"0","summary":"NovaBridge reported that Chu Denny Hsueh Wen, EVP and Head of Strategic Partnership, filed an initial Form 3 statement of beneficial ownership.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL2SZ0NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2620292194","title":"NovaBridge Biosciences General Counsel Lin Liwei Lorraine Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292194","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292194?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:45","pubTimestamp":1773884729,"startTime":"0","endTime":"0","summary":"Lorraine Lin Liwei filed an initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026.She is listed as an officer with the title of General Counsel.The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL73tVz8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2620292918","title":"NovaBridge Biosciences CEO and Director Xi-Yong Fu files Form 3 initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292918","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292918?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:44","pubTimestamp":1773884694,"startTime":"0","endTime":"0","summary":"Xi-Yong Fu filed an initial statement of beneficial ownership for NovaBridge Biosciences and is listed as Chief Executive Officer and Director.The filing reported 59,823 ordinary shares beneficially owned directly.It also reported employee share options covering 1.25 million ordinary shares at an exercise price of USD 1.07.Restricted share units covering 1.25 million ordinary shares were also reported.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL5tXpmZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2620292538","title":"NovaBridge Biosciences director Emmett Cunningham files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292538","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292538?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884205,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Emmett Cunningham filed an initial statement of beneficial ownership as a director. The filing disclosed a 2025 employee share option covering 120,000 shares with an exercise price of USD 3.21. The option has an expiration date of Feb. 17, 2036.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL275g0q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2620925802","title":"NovaBridge Biosciences Files Form 3 for SVP of Clinical Development Claire Xu Cong","url":"https://stock-news.laohu8.com/highlight/detail?id=2620925802","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620925802?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:36","pubTimestamp":1773884166,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Claire Xu Cong filed an initial statement of beneficial ownership as an officer. The filing lists her role as Senior Vice President, Clinical Development. Claire Xu Cong reported direct ownership of 288,266 ordinary shares. She also reported employee share options covering 22,900 ADSs at an exercise price of USD 61 and 43,690 ADSs at an exercise price of USD 21.15. The filing also reported restricted share units for 36,716 ADSs and 5,405 ADSs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commissi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3q83cM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2620292872","title":"NovaBridge Biosciences files initial beneficial ownership statement for Global Controller Adeline Yi Zhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292872","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292872?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:32","pubTimestamp":1773883953,"startTime":"0","endTime":"0","summary":"NovaBridge Biosciences reported that Adeline Yi Zhang filed an initial statement of beneficial ownership. Zhang is listed as an officer with the title Global Controller. The filing stated that no securities are beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Q8VK0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2620942702","title":"NovaBridge Biosciences Director Au Chun Kwok Alan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620942702","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620942702?lang=en_us&edition=fundamental","pubTime":"2026-03-19 09:25","pubTimestamp":1773883528,"startTime":"0","endTime":"0","summary":"Alan Au Chun Kwok filed a Form 3 initial statement of beneficial ownership for NovaBridge Biosciences on 03/18/2026. The filing identifies Au as a director. Au reported a 2024 employee share option for 114,093 shares with an exercise price of USD 1.22. Au also reported a 2025 employee share option for 34,530 shares with an exercise price of USD 3.86.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NovaBridge Biosciences published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1Wzn3S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2620467727","title":"NovaBridge Biosciences Price Target Maintained With a $9.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620467727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620467727?lang=en_us&edition=fundamental","pubTime":"2026-03-17 00:30","pubTimestamp":1773678600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NBP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 12:30 ET (16:30 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP"],"gpt_icon":0},{"id":"2619546825","title":"Novabridge Biosciences:  FDA Confirmed Givastomig’s Potential Eligibility for an Accelerated Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619546825?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2619346826","title":"Novabridge Biosciences: Expects to Initiate a Registrational Phase 3 Combination Trial as Early as Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619346826","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619346826?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:35","pubTimestamp":1773664532,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4040K9:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2619450803","title":"BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450803","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450803?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:36","pubTimestamp":1773660985,"startTime":"0","endTime":"0","summary":"BRIEF-NovaBridge Announces Productive FDA Type B Meeting On Potential Accelerated Approval Pathway For Givastomig In Gastric CancerMarch 16 (Reuters) - NovaBridge Biosciences NBP.O:NOVABRIDGE ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0},{"id":"2619524784","title":"NovaBridge plans Q4 2026 Phase 3 trial of givastomig in first-line gastric cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619524784","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619524784?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:04","pubTimestamp":1773659054,"startTime":"0","endTime":"0","summary":"NovaBridge reported that the FDA provided alignment in a Type B meeting on the potential eligibility of givastomig for an accelerated approval pathway in first-line Her2-, CLDN 18.2+, PD-L1+ gastroesophageal cancer. The company said the pathway would be supported by a registrational Phase 3 combination trial using objective response rate as a primary endpoint, which it expects to start as early as Q4 2026. NovaBridge stated that the accelerated approval discussions build on results from a Phase 1b combination trial that have already been presented. Phillip Dennis, Chief Medical Officer, said the company plans to continue discussions with the FDA on final Phase 3 study design details.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL7DSH1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014005.SGD","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","BK4585","IE00BN0W2V16.EUR","SG9999014013.SGD","NBP","IE00B64PRP62.GBP","SG9999014021.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","BK4139"],"gpt_icon":0},{"id":"2619683452","title":"Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2619683452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619683452?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2619521804","title":"Novabridge Biosciences - FDA Confirms Givastomig Eligible for Accelerated Approval Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2619521804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619521804?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2619452136","title":"Novabridge Biosciences - to Initiate Registrational Phase 3 Combination Trial in Q4 2026 Using Orr as Primary Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452136?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA5VSGVC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NBP"],"gpt_icon":0},{"id":"2619193779","title":"Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193779","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619193779?lang=en_us&edition=fundamental","pubTime":"2026-03-13 18:05","pubTimestamp":1773396300,"startTime":"0","endTime":"0","summary":"VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor. Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD. VIS-101 demonstrated mean BVCA improvements of >10 ETDRS letters and median CST reductions of 100-150 mm. Potentially best-in-class durability with a favorable safety profile and no dose-limiting toxicity. Phase 2b dose-determining study expected to begin in H2 2026; global Phase 3 program expected to begin in 2027. SHANGHAI, March 13, 2026 /PRNewswire/ --Everest Medicines  today announced that its licensing partner, NovaBridge Biopharma , together with its subsidiary Visara, Inc. , reported positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration , diabetic macular edema , and retinal vein occlusion . Topl","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/everest-medicines-licensing-partner-novabridge-and-visara-announce-positive-results-from-vis-101-phase-2a-wet-amd-study-302713298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1803068979.SGD","LU0109392836.USD","LU2264538146.SGD","BK4532","AMDY","AMDW","IE00B5949003.HKD","BK4534","LU0082616367.USD","LU0823421333.USD","LU1880398554.USD","LU2360106780.USD","BK4512","BK4573","LU1064131342.USD","AMDU","LU2458330169.SGD","BK4588","BK4575","LU1242518931.SGD","BK4605","LU1989764664.SGD","LU0274383776.USD","LU2054465674.USD","BK4566","BK7095","LU1861559042.SGD","LU2355687059.USD","AMDL","LU0056508442.USD","LU0642271901.SGD","LU1861558580.USD","NBP","LU0823434583.USD","BK4554","LU1923623000.USD","LU2931357623.SGD","IE00BMPRXN33.USD","LU0127658192.USD","LU1880398471.USD","LU0390134368.USD","LU0719512351.SGD","LU1852331112.SGD","LU0081259029.USD","LU1242518857.USD","LU2250418816.HKD","BK4529","AMDG","IE0004445239.USD","AMYY","BK4614","DAMD","LU1951198990.SGD","IE0009356076.USD","LU1303367103.USD","LU2098885051.SGD","LU2458330243.SGD","LU0823421416.USD","BK4612","01952","AMUU","BK4543","LU0979878070.USD","AMDD","BK4141","LU0198837287.USD","LU0889565833.HKD","LU1951200564.SGD","BK4585","LU1988902786.USD","LU2089985449.USD","IE00BMPRXR70.SGD","LU0823434740.USD","LU1316542783.SGD","BK4139"],"gpt_icon":0},{"id":"2618620753","title":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow","url":"https://stock-news.laohu8.com/highlight/detail?id=2618620753","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618620753?lang=en_us&edition=fundamental","pubTime":"2026-03-09 23:46","pubTimestamp":1773071217,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, DowWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https:/","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX16R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COHX","NEM","COP","NBP","AAL","LYV","XENE","LITX","DAL","HIMY","VRT","AALG","HMYY","DOW","RAPP","DE","JPMO","CAPR","PLD","SLB","UAL","XOMX","LUV","RGNX","RLMD","SATG","HIMZ","SATS","XOMO","DTIL","IRON","XOMZ","BAC","VRTL","NWMX","DUK","JEF","ITT","FCEL","AGH","CDE","CAT","PFE","HL","NEMG"],"gpt_icon":1},{"id":"2618271622","title":"Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2618271622","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618271622?lang=en_us&edition=fundamental","pubTime":"2026-03-09 22:24","pubTimestamp":1773066240,"startTime":"0","endTime":"0","summary":"NovaBridge stock jumps after VIS-101 Phase 2a study shows strong vision improvement in wet age-related macular degeneration patients.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Genetic-eye-disease-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Genetic-eye-disease-research.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51129866/mid-cap-novabridge-biosciences-stock-jumps-fueled-by-positive-study-data-in-eye-disease","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51129866/mid-cap-novabridge-biosciences-stock-jumps-fueled-by-positive-study-data-in-eye-disease","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","CST","BK4217","NBP","SMA"],"gpt_icon":0},{"id":"2618621571","title":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge","url":"https://stock-news.laohu8.com/highlight/detail?id=2618621571","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618621571?lang=en_us&edition=fundamental","pubTime":"2026-03-09 21:29","pubTimestamp":1773062964,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridgeWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL6N3ZX0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235303.USD","LU0203345920.USD","HMYY","LUV","DAL","LITX","LU0997586606.USD","UAL","LYV","NEM","XOMO","HIMS","AU","PFE","AGH","SATG","VRT","FCEL","BARC.UK","AALG","VRTL","LU0868494708.USD","BK4017","CDE","SLB","HIMZ","XOMZ","DTIL","NBP","NWMX","ITT","NEMG","HIYY","CAT","SATS","RAPP","XOMX","HIMY","RLMD","XENE","AAL","COHX","PLD","IE00B19Z3581.USD","HL","COP"],"gpt_icon":1},{"id":"2618628309","title":"BUZZ-NovaBridge gains as eye disease drug shows promise in mid‑stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628309","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628309?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:17","pubTimestamp":1773055058,"startTime":"0","endTime":"0","summary":"BUZZ-NovaBridge gains as eye disease drug shows promise in midstage trial** Shares of drug developer NovaBridge NBP.O rise 6.6% to $3.73 premarket** Co says its experimental drug, VIS-101, improved vision in people with wet age-related macular degeneration, a disease that damages the retina and causes vision loss in older adults** Adds patients gained more than 10 letters on a standard eye chart and had reduced retinal swelling in a mid-stage study ** Says nearly half of the 38 patients in the trial needed no additional treatment for six months after three doses** VIS101 well tolerated with no serious safety issues - co ** NBP plans larger dose-finding study in second-half of 2026 and global late-stage trial in 2027** Shares rose nearly four-fold in 2025  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX10Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBP","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":69,"code":"91000000","status":"200"}]}}